IL139921A0 - Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma - Google Patents

Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma

Info

Publication number
IL139921A0
IL139921A0 IL13992199A IL13992199A IL139921A0 IL 139921 A0 IL139921 A0 IL 139921A0 IL 13992199 A IL13992199 A IL 13992199A IL 13992199 A IL13992199 A IL 13992199A IL 139921 A0 IL139921 A0 IL 139921A0
Authority
IL
Israel
Prior art keywords
formoterol
budesonide
asthma
prevention
treatment
Prior art date
Application number
IL13992199A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20411658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL139921(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL139921A0 publication Critical patent/IL139921A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL13992199A 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma IL139921A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802073A SE9802073D0 (sv) 1998-06-11 1998-06-11 New use
PCT/SE1999/001031 WO1999064014A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma

Publications (1)

Publication Number Publication Date
IL139921A0 true IL139921A0 (en) 2002-02-10

Family

ID=20411658

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13992199A IL139921A0 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
IL139921A IL139921A (en) 1998-06-11 2000-11-27 Use of a preparation containing formoterol and budesonide for the manufacture of a drug for the prevention or treatment of an extreme condition of asthma

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL139921A IL139921A (en) 1998-06-11 2000-11-27 Use of a preparation containing formoterol and budesonide for the manufacture of a drug for the prevention or treatment of an extreme condition of asthma

Country Status (35)

Country Link
US (2) US20010049396A1 (ar)
EP (3) EP1316311A1 (ar)
JP (1) JP2002517450A (ar)
KR (1) KR20010052721A (ar)
CN (1) CN100389771C (ar)
AR (1) AR018410A1 (ar)
AT (1) ATE389409T1 (ar)
AU (1) AU771715B2 (ar)
BR (1) BR9911073A (ar)
CA (1) CA2334411C (ar)
CY (1) CY1110376T1 (ar)
CZ (1) CZ300874B6 (ar)
DE (1) DE69938390T2 (ar)
DK (1) DK1085877T3 (ar)
EE (1) EE05661B1 (ar)
ES (1) ES2302384T3 (ar)
HK (1) HK1035145A1 (ar)
HU (1) HUP0103108A3 (ar)
ID (1) ID27937A (ar)
IL (2) IL139921A0 (ar)
IS (1) IS5752A (ar)
MY (1) MY129281A (ar)
NO (3) NO20006253L (ar)
NZ (1) NZ536279A (ar)
PL (1) PL344665A1 (ar)
PT (1) PT1085877E (ar)
RU (1) RU2222332C2 (ar)
SA (1) SA99200234B1 (ar)
SE (1) SE9802073D0 (ar)
SK (1) SK286252B6 (ar)
TR (1) TR200003666T2 (ar)
TW (1) TWI252756B (ar)
UA (1) UA87956C2 (ar)
WO (1) WO1999064014A1 (ar)
ZA (1) ZA200006943B (ar)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
ME00220B (me) 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
SI1273292T1 (en) 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
ATE401058T1 (de) * 2001-11-01 2008-08-15 Nektar Therapeutics Sprühtrocknungsverfahren
FI20020126A0 (fi) * 2002-01-23 2002-01-23 Orion Corp Koostumuksia pulmonaaliseen antoon
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
EP2425820B1 (en) 2007-02-11 2015-04-08 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
KR20090121338A (ko) 2007-02-19 2009-11-25 씨아이피엘에이 엘티디. 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
CA2763939A1 (en) 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
PL2538922T3 (pl) * 2010-02-25 2016-11-30 Formułowanie kompozycji do leczenia stanów zapalnych
EP2593108A2 (en) * 2010-07-16 2013-05-22 Cilpa Limited Pharmaceutical compositions comprising r(+) budesonide and one or more bronchodilators
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
ES2899621T3 (es) 2010-09-29 2022-03-14 Pulmatrix Operating Co Inc Polvos secos catiónicos que comprenden sal de magnesio
RU2017144619A (ru) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
WO2013130767A1 (en) 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
IT202000006442A1 (it) * 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203401A (en) 1979-01-29 1980-05-20 General Motors Corporation Evaporative emissions canister
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
JP3042866B2 (ja) 1989-09-08 2000-05-22 グラクソ・グループ・リミテッド 呼吸疾患治療薬
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5119791A (en) 1991-06-07 1992-06-09 General Motors Corporation Vapor storage canister with liquid trap
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
CA2356145A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
EP0613371B1 (en) 1991-12-18 2002-03-06 AstraZeneca AB New combination of formoterol and budesonide
US5408977A (en) 1993-08-23 1995-04-25 Walbro Corporation Fuel tank with carbon canister and shut-off valve
HU222355B1 (hu) 1993-10-01 2003-06-28 Astra Aktiebolag Eljárás és berendezés finom gyógyszerhatóanyag-porok kezelésére és feldolgozására
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5511957A (en) 1994-09-27 1996-04-30 Walbro Corporation High capacity fuel pump and filter combination
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
CN1207730A (zh) 1995-11-24 1999-02-10 史密丝克莱恩比彻姆股份公司 喹啉衍生物
US5651349A (en) 1995-12-11 1997-07-29 Chrysler Corporation Purge system flow monitor and method
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
TR199903272T2 (xx) 1997-06-27 2000-08-21 Astra Aktiebolag Ast�m kar��t� ila�lar�n yeni bile�imleri.
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US5957114A (en) 1998-07-17 1999-09-28 Ford Motor Company Evaporative emission canister for an automotive vehicle
US5924410A (en) 1998-07-20 1999-07-20 Ford Motor Company Evaporative emission canister for an automotive vehicle
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6227862B1 (en) * 1999-02-12 2001-05-08 Advanced Drivers Education Products And Training, Inc. Driver training system
DE60016990T2 (de) 1999-02-26 2005-12-29 Walbro Corp., Cass City Fahrzeugbrennstoffsystem
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
US6237574B1 (en) 1999-04-20 2001-05-29 Ford Motor Company Evaporative emission canister for an automotive vehicle
US6136075A (en) 1999-05-03 2000-10-24 Westvaco Corporation Automotive evaporative emissions canister adsorptive restraint system
JP3646217B2 (ja) 1999-07-08 2005-05-11 愛三工業株式会社 キャニスタモジュール
US6374811B1 (en) 2000-10-04 2002-04-23 Ford Global Technologies, Inc. System and method for minimizing fuel evaporative emissions from an internal combustion engine

Also Published As

Publication number Publication date
EP1085877B1 (en) 2008-03-19
BR9911073A (pt) 2001-02-20
UA87956C2 (uk) 2009-09-10
NO20006253L (no) 2001-02-12
MY129281A (en) 2007-03-30
NZ536279A (en) 2007-01-26
CA2334411A1 (en) 1999-12-16
HUP0103108A2 (hu) 2002-05-29
IS5752A (is) 2000-12-05
TR200003666T2 (tr) 2001-06-21
US20010049396A1 (en) 2001-12-06
EP1085877A1 (en) 2001-03-28
PT1085877E (pt) 2008-05-13
EP1316311A1 (en) 2003-06-04
HK1035145A1 (en) 2001-11-16
CN100389771C (zh) 2008-05-28
PL344665A1 (en) 2001-11-19
IL139921A (en) 2006-10-05
SK286252B6 (sk) 2008-06-06
KR20010052721A (ko) 2001-06-25
HUP0103108A3 (en) 2002-11-28
CY1110376T1 (el) 2015-04-29
CN1305380A (zh) 2001-07-25
SA99200234B1 (ar) 2007-03-10
SK18882000A3 (sk) 2001-07-10
JP2002517450A (ja) 2002-06-18
EE200000740A (et) 2002-04-15
AU4671099A (en) 1999-12-30
TWI252756B (en) 2006-04-11
CA2334411C (en) 2008-07-15
NO20130269L (no) 2001-02-12
ID27937A (id) 2001-05-03
US9295644B2 (en) 2016-03-29
DK1085877T3 (da) 2008-06-09
US20040063676A1 (en) 2004-04-01
EP2266574A1 (en) 2010-12-29
EE05661B1 (et) 2013-06-17
AU771715B2 (en) 2004-04-01
ZA200006943B (en) 2002-02-27
DE69938390T2 (de) 2009-03-05
DE69938390D1 (de) 2008-04-30
NO20140823L (no) 2001-02-12
AR018410A1 (es) 2001-11-14
ES2302384T3 (es) 2008-07-01
WO1999064014A1 (en) 1999-12-16
RU2222332C2 (ru) 2004-01-27
ATE389409T1 (de) 2008-04-15
CZ300874B6 (cs) 2009-09-02
CZ20004593A3 (cs) 2001-04-11
SE9802073D0 (sv) 1998-06-11
NO20006253D0 (no) 2000-12-08

Similar Documents

Publication Publication Date Title
IL139921A0 (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
IL134773A0 (en) New use for budesonide and formoterol
HK1042429A1 (en) Combinations of formoterol and fluticasone propionate for asthma.
HUP0200142A2 (en) Combinations of formoterol and mometasone furoate for asthma
HUP0200014A3 (en) Pharmaceutical aerosol compositions containing fluoroalkanes, budesonide and formoterol
HUP0104676A3 (en) Compositions for the treatment of anorectal disorders and their use
AU4671601A (en) Medical combinations comprising formoterol and budesonide
IL112205A0 (en) Curcumin, analogues of curcumin and novel uses thereof
IL116505A0 (en) Compounds with progesterone-antagonistic and antiestrogenic action and the use thereof for the manufacture of pharmaceutical agents
HUP0104702A3 (en) Therapeutic agent for the suppression of snoring ntherapeutic agent for the suppression of snoring noises oises
HUP0104410A3 (en) A composition for the prevention and/or treatment of atherosclerosis
IL125446A0 (en) Pharmaceutical composition for the treatment of asthma allergy and inflammation
PL358375A1 (en) Medicaments for treating respiratory disorders comprising formoterol and fluticasone
PL365582A1 (en) Use of salmeterol and fluticasone propionate combination
AU4853801A (en) Medical combination comprising salmeterol and budesonide
AU4854101A (en) Medical combinations comprising formoterol and mometasone
SI1085877T1 (sl) Uporaba sestavka, ki obsega formoterol in budezonid, za preprečevanje ali zdravljenje akutnega stanja
AU3071899A (en) Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma
SI1152753T1 (en) Combinations of formoterol and fluticasone propionate for asthma
AU6230299A (en) Slimming health band and use of the same
SI1156790T1 (en) Combinations of formoterol and mometasone furoate
SI1126867T1 (en) A composition for the prevention and/or treatment of atherosclerosis
HUP9903881A3 (en) Benzenesulfonamide derivatives usable for the prevention and/or treatment of thrombosis, asthma or allergic and use thereof
ZA951B (en) Curcumin analogues of curcumin and novel uses thereof

Legal Events

Date Code Title Description
EXTN Extension order renewed
FF Patent granted
KB Patent renewed